Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01100658 · ClinicalTrials.gov registry record · NA

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

A NA study, sponsored by University of Minnesota.

Terminated
Registry status
NA
Development phase
1
Enrollment target

NCT01100658 is a NA study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 1 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01100658, a NA study, was terminated before completion, sponsored by University of Minnesota.

TERMINATED
Registry status
NA
Development phase
1 participants
Enrollment target

Study Summary

While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention deficits in this population. Numerous studies have examined the effectiveness of methylphenidate in the treatment of children with attention deficit hyperactivity disorder (ADHD). However, the effectiveness of this medication for improving attention and behavioral functioning in children with medical illnesses or brain injury are less clear. Patients will be randomized to receive one week of Metadate CD (a controlled release form of methylphenidate, similar to Ritalin) and one week of placebo in a double-blind fashion.

Interventions

  • DRUG Placebo
  • DRUG Methylphenidate

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2010-05
Est. Completion 2010-11
Phase NA

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT01100658

The ClinicalTrials.gov registry entry for NCT01100658 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01100658 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01100658 about?

NCT01100658 is a clinical study titled "Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors". While neurocognitive impairments in attention, memory and executive functioning are commonly reported sequelae of childhood leukemia and brain tumors, studies have only recently begun to examine the treatment of attention deficits in this population. Numerous studies have examined the effectiveness ...

What is the current status of trial NCT01100658?

This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2010-05. Estimated completion is 2010-11.

What interventions are being tested in trial NCT01100658?

The interventions under investigation include: Placebo (DRUG), Methylphenidate (DRUG).

Who is sponsoring clinical trial NCT01100658?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.